McHenry T. Tichenor, Jr. is an Independent Director of the Company. He has also served as the President of Tichenor Ventures, LLC since January 2010 and held a board observer role at Peloton Therapeutics, Inc. from October 2012 until its sale to Merck in July 2019. He served as a director of Belo Corp. from 2009 to 2013. Mr. Tichenor served as President, Chief Executive Officer and Director of Tichenor Media System, Inc. from 1981 to 1997, which he subsequently merged with the Hispanic Broadcasting Corporation and, ultimately, with Univision Communications. Mr. Tichenor currently serves as President of the Osteosarcoma Institute and the Executive Director of WWWW Foundation, Inc., non-profit organizations devoted, in part, to cancer research. From 2010 to 2018, Mr. Tichenor served as Board Chairman of the Sarcoma Alliance for Research through Collaboration, a non-profit sponsor of clinical trials for the prevention, treatment and cure of sarcomas. Mr. Tichenor earned a B.A. with Honors in Plan II and an M.B.A. from The University of Texas at Austin, and an M.S. in biotechnology from The University of Texas at Dallas.
As the Independent Director of Ngm Biopharmaceuticals Inc, the total compensation of McHenry Tichenor at Ngm Biopharmaceuticals Inc is 241,118$. There are 8 executives at Ngm Biopharmaceuticals Inc getting paid more, with David Woodhouse having the highest compensation of 2,092,150$.
McHenry Tichenor is 64, he's been the Independent Director of Ngm Biopharmaceuticals Inc since 2018. There are 1 older and 16 younger executives at Ngm Biopharmaceuticals Inc. The oldest executive at Ngm Biopharmaceuticals Inc is David Goeddel, 68, who is the Lead independent director.
Mchenry's mailing address filed with the SEC is 100 Crescent Ct #700, Dallas, TX 75201, USA.
Over the last 6 years, insiders at Ngm Biopharmaceuticals Inc have traded over 9,159,599$ worth of Ngm Biopharmaceuticals Inc stock and bought 18,889,291 units worth 177,396,366$ . The most active insiders traders include Peter Svennilson、David V Goeddel、Group L P Svennilson Peter .... On average, Ngm Biopharmaceuticals Inc executives and independent directors trade stock every 9 days with the average trade being worth of 171,092$. The most recent stock trade was executed by Group L Ptcg Opportunity Ii... on 15 November 2023, trading 22,631 units of NGM stock currently worth 15,615$.
ngm bio is a research-driven, clinical stage biopharmaceutical company with a drug discovery platform designed to generate a pipeline of first-in-class biologic drug candidates. our initial r&d focus has been on cardio-metabolic and liver disease, but we believe that our research expertise – comprehensive and grounded in fundamental, interrelated mechanisms of human biology – is capable of driving the development of new therapies for a wide range of disease areas such as cancer. ngm bio’s comprehensive approach to drug discovery focuses on elucidating the biology of hormones, cell receptors and associated ligands. as we investigate these novel biological mechanisms, we assemble a deep understanding of the relationship between the structure and function of proteins of interest. coupled with our experience in protein and antibody engineering, our approach enables the efficient and targeted generation of potential first-in-class therapeutics with optimized pharmacologic profiles. work
Ngm Biopharmaceuticals Inc executives and other stock owners filed with the SEC include: